Kornimate/medical-research-clean huggingface dataset:
macrophage activation markers in covid-19 patients

Conditions: COVID-19

Summary: this study is aiming to find the relation between the severity of covid-19 in diabetic and obese patients and the high serum levels of matrix metalloproteinase-7 (mmp-7),matrix metalloproteinase-9 (mmp-9), tgf-β and pdgf macrophage activation markers

acute respiratory distress syndrome (ards) commonly occurs in covid-19 patients who are diabetic and obese, ards is characterized by inflammation and pulmonary fibrosis mediated by cytokines and biomarkers released from activated alveolar macrophages, also cytokine storm may occurs leading to multiple organ failure. these sequelae of covid-19 disease in obese and diabetic patients are attributed to elevated plasma lipopolysaccharide which is the main activator of m1 and m2 macrophages. chronic activation of macrophages leads to production of profibrotic markers as transforming growth factor-β (tgf-β), platelet-derived growth factor (pdgf), matrix metalloproteinase-7 (mmp7) and matrix metalloproteinase-9 (mmp9) which promote fibrogenesis. in this research, we measure circulatory alveolar macrophage activation markers in covid-19 obese patients with type 1 and type 2 diabetes.

Eligibility criteria:
inclusion criteria: * overweight patients with body mass index higher than 25 and obese patients with body mass index higher than 30 were selected to be included * type one and type two diabetes mellitus patients were also included exclusion criteria: -
soft tissue outcomes of badly broken-down teeth treated with orthodontic extrusion compared with immediate implant placement

Conditions: Broken Teeth

Summary: many patients suffer from tooth substance loss as a result of fracture or decay of teeth situated in the esthetic zone. this might commonly occur with car accidents, sport injuries, falls or even fistfights. for those patients, most of the crown is lost and only the root remains, so there is no enough ferrule in order to restore the tooth with a crown. the most common treatment for those patients is immediate single-tooth implant. however, some problems may arise such as: high treatment expenses, the need for bone augmentation, the refill of the papilla to its normal position may be questionable in some implant cases, young growing patients, apprehensive patients, dental facilities and rural areas lacking cone beam computed tomography (cbct) machines. accordingly, orthodontic extrusion may be an alternative attempt to preserve the tooth by traction of the remaining root to create a sufficient ferrule effect to restore the tooth.


Eligibility criteria:
inclusion criteria: * patients at 20-40 years old and have no history of periodontal disease. (periodontally healthy patients). * single rooted teeth with adjacent intact or restored neighboring teeth, more than one tooth may be included in the same arch. * more than 1:1 crown root ratio, so that the c/r is 1:1 after extrusion and restoration. * presence of intact adjacent teeth. exclusion criteria: * badly broken-down teeth with active signs of infection. * teeth with vertical root fracture. * teeth with severely tapered roots.. * diabetic patients, assessed by measuring glycosylated hemoglobin (hba1c). patients with an hba1c level greater than 8 will be excluded. * potentially uncooperative patients who are not willing to go through the proposed interventions (patients who will refuse to undergo orthodontic treatment). * moderate-to-heavy daily smokers\* (who report consuming at least 11 cigarettes/day). * patients with systemic disease that may affect normal healing. * psychiatric problems, emotional instability, and unrealistic esthetic demands. * history of radiation therapy to the head and neck, or bone augmentation to implant site. * labial cortical bone fenestration diagnosed from cbct. * bruxism.
5fu and octreotide long-acting release (lar) for neuroendocrine tumors

Conditions: Neuroendocrine Tumors

Summary: well differentiated neuroendocrine carcinomas have low proliferative activity and conventional chemotherapy is not recommended. metronomic chemotherapy, i.e. the frequent administration of cytotoxic drugs at low doses, has demonstrated antiangiogenetic properties. since well differentiated ne carcinomas are highly vascular, there is a rationale for testing metronomic chemotherapy in this clinical setting. a phase ii study was designed to test the activity of protracted 5-fluorouracil (5fu) infusion plus long-acting release (lar) octreotide for patients with neuroendocrine carcinoma.

metastatic or locally advanced well differentiated neuroendocrine carcinoma were treated with 5fluorouracil protracted intravenous infusion (200 mg/m2 daily) plus octreotide lar (20 mg monthly). primary endpoint: the response to treatment, evaluated according to the recist criteria. secondary endpoints: * toxicity, graded according to the nci-ctg criteria; * symptomatic response: evaluated according to the changes in both the frequency and intensity of symptoms; * biochemical response: evaluated considering the changes in the tumor marker levels (circulating chromogranin a); * time to progression and survival: were measured from the date of treatment start to the date of progression and the date of last follow-up or death, respectively.

Eligibility criteria:
inclusion criteria: * histological diagnosis of well-differentiated neuroendocrine carcinoma according to the world health organization (who) classification; * locally advanced or metastatic disease not amenable to surgery with radical intent; * at least one measurable target lesion; * radiological documentation of progressive disease; * ecog performance status grade \<=2; * life expectancy \>12 weeks; * adequate bone marrow reserve; * adequate hepatic and renal function; * ability to comply with the protocol procedures (including geographic accessibility); * written informed consent. exclusion criteria: * non-malignant systemic disease or conditions that precluded patients from receiving the study therapy; * second primary malignancies and previous systemic antineoplastic treatment including somatostatin analogues; * history of prior malignancy, excepted for cured non-melanoma skin cancer, and cured in situ cervical carcinoma.

Keywords: octreotide lar neuroendocrine carcinoma metronomic 5fluorouracil
early percutaneous vertebroplasty versus standard conservative treatment in thoracolumbar vertebral fractures

Conditions: Vertebral Fracture

Summary: the aim of this study is to evaluate the efficacy of carrying out early vertebroplasty procedure, compared to the standard conservative treatment (corset), in order to prevent residual deformations that could occur in complications of vertebral fractures that are medically treated using a corset. this is a monocentric, randomized, parallel group, prospective and open-label study.

in this study, 58 patients with a vertebral fracture no more than 10 days old (with a max of 15 days old) will be enrolled. treatment will be randomly allocated in 2 groups: early percutaneous vertebroplasty (epv group) or standard conservative treatment (corset, ct group). patients will be followed up during 3 months after treatment. they will receive standard care for a vertebral fracture at the grenoble-alpes university hospital. evaluated criteria: vertebral kyphosis evolution, pain, efficacy and quality of vertebroplasty procedure, tolerance and observance of the standard treatment, safety, physical performance, quality of life, autonomy.

Eligibility criteria:
inclusion criteria: * age ≥ 50 years * fracture localisation : vertebrae from t8 to l5 * recent fracture (\< 10 days, maximum 15 days) * ct scan showing a fracture of the superior endplate and of the anterior cortex of the vertebral body of type a1 according to the magerl classification and vertebral kyphosis deformation \< 30° * patient affiliated to the french social security system or an equivalent system * patient who has signed consent form exclusion criteria: * multiple level fracture * repeated fracture at the same level * others peripheral fractures * contraindication for percutaneous procedure * contraindication for vertebroplasty procedure (pathology with risk of decompensation, coagulation problems, deformation considered by the surgeon to be inaccessible by vertebroplasty procedure, presence of an infected site) * contraindication for anasthesia * methylmethacrylate (mma) allergy known * impossibility to plan the start of the treatment (set up of treatment or carrying out of a vertebroplasty gesture) within a maximum deadline of 15 days after the fracture * body mass index (bmi) \> 31,5 * progressive local infection * progressive local cancer * patient presenting cognitive disorder with behavioural disorder which could disturb the treatment * non-cooperative patient * patient who can not be followed up at grenoble hospital during the 3 months of the study * patient concerned by articles l1121-5, l1121-6, l1121-8 of the french public health code

Keywords: vertebral fracture early percutaneous vertebroplasty standard conservative treatment kyphosis angle
the effect of ferric carboxymaltose on hemoglobin and blood transfusion in cardiac surgery

Conditions: Anemia

Summary: anemia after cardiac surgery is a vast phenomena. more than 70% of the patients who under went surgery represented with hemoglobin less than 8 mg/dl (the cutoff for blood transfusion) and more than 80% of the patients receives at least one unit of red blood cell transfusion. there were number of attempts to prevent the postoperative anemia by giving erythropoietin, iron per os and intra venus iron. non of the above have shown increase in hemoglobin after the cardiac surgery.

research objectives the study objectives are: 1. determine hemoglobin values in non-anemic patients given ferric carboxymaltose prior to and post heart surgery. 2. determine the effect of ferric carboxymaltose in non-anemic patients prior to surgery on the number of blood units administer postoperation. research methods prospective, randomized, double-blind, placebo-controlled research. all patients who are in the cardiac surgery department for bypass surgery, valve replacement surgery or combined surgery will be eligible to participate in the study. the study will be presented and explained to all patients and, if they consent, patients will be divided into two random groups. one group will receive ferinject iv 24-48 hours prior to surgery. the second group will receive a placebo drug in the same time period as when the drug ferinject is administered. the population studied all patients aged 18 or older hospitalized at the rambam medical center and are candidates for open-heart surgery (coronary artery bypass, valve, combined).

Eligibility criteria:
inclusion criteria: 1. age 18 and older 2. patient candidates for open heart surgery (coronary artery bypass, valve replacement, or a combination of both). 3. hemoglobin above 12g/dl in women and above than 13g\\dl in men. exclusion criteria: 1. patients who require emergency heart surgery. 2. patients who are not hemodynamically stable or intubated pre-operatively. 3. patients with a known sensitivity to iron. 4. patients with a known history of allergies (rashes, etc.). 5. patients with liver failure (alanine aminotransferase\> 3 times normal). 6. patients with cirrhosis. 7. patients with an active infection. 8. patients with rheumatoid arthritis and indications of an active infection. 9. pregnant women. 10. lactating women. 11. patients with anemia prior to surgery for any reason (b12 deficiency or folic acid deficiency). 12. patients participating in another drug trial. 13. patients treated with iron who took medication within the four weeks prior to surgery. 14. patients who received a blood transfusion in the four weeks prior to surgery.

Keywords: cardiac surgery hemoglobin iron
the effect of good bacteria on nonalcoholic fatty liver disease in diabetics

Conditions: Fatty Liver; Hepatic Steatosis; Diabetes Mellitus; Liver Diseases

Summary: the purpose of this study is to determine whether probiotics, bacteria that may improve liver health, can effectively treat a chronic condition in diabetics that increases fat in the liver.

nonalcoholic fatty liver disease (nafld) is the most common cause of chronic liver disease in the united states and is also common in diabetics; unfortunately, research on nafld has been limited. safe, inexpensive, and well-tolerated treatments for nafld are needed. recent studies indicate that probiotics help to improve fat breakdown in mice. this study will evaluate the efficacy of probiotic therapy to reduce fat accumulation in the livers of people with nafld and diabetes. participants in this study will be randomly assigned to receive either a probiotic-containing mixture or placebo once daily for 6 months. blood tests, and magnetic resonance spectroscopy will be used to assess participants at study start and at study completion.

Eligibility criteria:
inclusion criteria: * nonalcoholic fatty liver disease exclusion criteria: * any cause of liver disease other than hepatic steatosis * diabetes * known or suspected cirrhosis * inability or unwillingness to undergo magnetic resonance procedures * requirement of long-term antibiotic therapy * pregnancy, breast-feeding, or plans to become pregnant

Keywords: probiotics bacteria
prevention of ventilator associated pneumonia with toothbrushing in oral care of critically ill mechanically ventilated patients

Conditions: Critical Care; Mechanical Ventilation; Ventilator Associated Pneumonia Prevention; Toothbrushing; Oral Care

Summary: effect of toothbrushing in oral care of mechanically ventilated critically ill patients on prevention of ventilator associated pneumonia

prospective, before and after study in 5 intensive care units (icus) of a university hospital. the before period (control phase, 6 months): standard oral care 3 times a day in every consecutive intubated patients in the participating icus the interphase period (1 month): formal training of all the nurses, physicians and residents on the use of toothbrushing during oral care the after period: (study phase, 6 months): standard oral care with tooth brushing 3 times a day in every consecutive intubated patients in the participating icus

Eligibility criteria:
inclusion criteria: * adult patients * intubated mechanically ventilated icu patient * platelets count \>50g/l exclusion criteria: * edentulous patients

Keywords: critical care mechanical ventilation ventilator associated pneumonia oral care
the healthy options feasibility study

Conditions: Obesity; Sedentary Lifestyle; Dyslipidemia; Hypertension; Cigarette Smoking; Diabetes

Summary: the investigators hypothesize that having health care providers other than physicians within a "groupe de médecine de famille" conduct cardiovascular risk assessments and teach lifestyle interventions to primary prevention patients will increase the likelihood that patients will adopt and maintain healthy lifestyles. these objectives will be supported by providing subjects with a cardiovascular risk profile estimating the subject's risk of cardiovascular disease and teaching them how to use the resources related to lifestyle changes available on the www.myhealthcheckup.com web site.


Eligibility criteria:
inclusion criteria: * male or female subjects 30-79 years of age without known cardiovascular disease but with one or more risk factors such as obesity, a sedentary lifestyle, dyslipidemia, hypertension, cigarette smoking, or diabetes * have provided informed consent * recent (past 6 months) fasting lipid profile results in the medical charts exclusion criteria: * unable or unlikely to follow and/or complete study or evidence of uncooperative attitude * subject is not literate in either french or english * subject does not have easy and regular access to the internet * exercise or weight loss are contra-indicated for medical reasons

Keywords: primary prevention patient knowledge nurse exercise smoking cessation weight loss
a promising tool for predicting consciousness evolution in prolonged disorders of consciousness

Conditions: Disorder of Consciousness

Summary: the research contains two parts. part 1: to explore whether eeg responses to zolpidem can assess consciousness circuit integrity and predict the evolution of consciousness in patients with prolonged disorders of consciousness; part 2: to explore if quantitative eeg reactivity might predict the prognosis of disorders of consciousness.


Eligibility criteria:
inclusion criteria: * presence of unresponsive wakefulness syndrome (uws) or minimally conscious state (mcs) on admission; * time since onset \> 4 weeks; * no history of neurodegenerative or psychiatric diseases. exclusion criteria: * allergic to zolpidem; * currently receiving zolpidem or related benzodiazepines; * diagnosed with seizure or status epilepticus.

Keywords: prolonged disorders of consciousness zolpidem eeg prognosis unresponsive wakefulness syndrome minimally conscious state
bioavailability of ibuprofen enantiomers compared with standard brufen sirup in healthy male volunteers

Conditions: Healthy

Summary: pharmacokinetics (relative bioavailability), safety and tolerability


Eligibility criteria:
inclusion criteria: * healthy males from 21 to 50 years and within +-20% of their normal weight (broca index) * written informed consent exclusion criteria: * any findings of the medical examination or laboratory tests deviating from normal and of clinical relevance * gastrointestinal, hepatic, renal, respiratory (especially bronchial asthma and chronic obstructive pulmonary disease), cardiovascular, metabolic, immunological or hormonal disorders * diseases of the central nervous system (such as epilepsy) or psychiatric disorders * history of orthostatic hypotension, fainting spells or blackouts * chronic or relevant acute infections * history of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * intake of a drug with a long half-life (\>=24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study * use of any drugs which might influence the results of the trial within seven days prior to administration or during the trial * participation in another trial with an investigational drug within two months prior to the start of the study * smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day) * inability to refrain from smoking on study days * alcohol abuse * drug abuse * blood donation (\>100 ml) within four weeks prior to administration * other disease or abnormality of clinical relevance * excessive physical activities within two weeks prior to administration or during the trial
ctx-4430 for the treatment of moderate to severe facial acne vulgaris

Conditions: Acne Vulgaris

Summary: a multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and safety study of oral ctx-4430 for the treatment of moderate to severe facial acne vulgaris.


Eligibility criteria:
inclusion criteria: 1. must provide informed consent. 2. male or female aged 16 to 44 inclusive. 3. moderate to severe facial acne vulgaris as defined in the protocol. exclusion criteria: 1. positive testing for hiv, hbsag, or hepatitis c virus (hcv). 2. females who are pregnant, lactating, or planning to become pregnant during the study. 3. any systemic medical condition which, in the opinion of the investigator, would put the participant at risk by participation in the study. 4. any systemic or dermatologic disorder that, in the opinion of the investigator will interfere with the assessment of the study endpoints (e.g. psoriasis). 5. concurrent or previous use of an investigational drug or device within 30 days prior to screening. 6. the presence of acne conglobata, acne fulminans, secondary acne, or nodulocystic acne. 7. the presence of known or suspicious unresolved dermatological cancerous or pre-cancerous lesions. 8. hypersensitivity or idiosyncratic reaction to compounds related to ctx-4430 or any of its components.

Keywords: facial acne
a study of the safety and efficacy of anacetrapib (mk-0859) when added to ongoing statin therapy in japanese participants with dyslipidemia (mk-0859-051 am1)

Conditions: Dyslipidemia

Summary: this study will evaluate the effects of anacetrapib (mk-0859) on low-density lipoprotein-cholesterol (ldl-c) when compared to placebo in japanese participants with dyslipidemia when added to an existing statin-modifying therapy.


Eligibility criteria:
inclusion criteria: * if female, cannot be of reproductive potential * treatment with an appropriate, stable dose of statin ± other lipid modifying therapy for at least 6 weeks and who is not at ldl-c goal per their category in the japan atherosclerosis society guidelines exclusion criteria: * previously participated in a study with a cholesteryl ester transfer protein (cetp) inhibitor * homozygous and heterozygous familial hypercholesterolemia * severe chronic heart failure * uncontrolled cardiac arrhythmias, myocardial infarction (mi), percutaneous coronary intervention (pci), coronary artery by-pass graft (cabg), unstable angina, or stroke within 3 months
effects of partial sleep deprivation on cognitive function of anesthesiologists

Conditions: Cognitive Dysfunction; Sleep Deprivation

Summary: the purpose of this study was to evaluate differences in cognitive functions at baseline and following night shift at a trauma center among faculty anesthesiologists.

anesthesiology is one of the few health-care professions that often demands split-second decisions. this is especially true in a trauma setting where the situation in the operating room can change drastically in a few seconds. anesthesiologists who cover trauma calls overnight are subject to long work shifts and demanding schedules that may adversely affect their performance. in combination with the disruption of circadian rhythm that can occur with night shift work, decline in performance from the long work shifts can lead to errors in judgment. an anonymous questionnaire included two groups of different items were used. items of the first group are about the personal data i.e. age, sex, marital status and parenting status, consumption behavior (tea, coffee, carbonated drinks, tobacco, anxiolytics, antidepressants, psychotropic agents and sport), and professional activity (number of extended worked shifts per month, number of weekends worked per month). items of the second group are related to the night shift itself i.e. number of cases, and the rest hours during the shift. psychomotor vigilance task, karolinska sleepiness scale, epworth sleepiness scale and trail making test before and after the shift were performed.

Eligibility criteria:
inclusion criteria: * full-time faculty anesthesiologists employed at kasr el- ainy hospital. * both genders * ages of 25-28 years. * varying levels of experience. exclusion criteria: * history of chronic neurological disease. * history of psychiatric disorders such as: * episode of major depression within the past 2 years. * lifetime history of schizophrenia. * other psychotic illness or bipolar illness.
renal function measurements in children

Conditions: Renal Function Disorder

Summary: the purpose of this study is to validate a feasible, safe and reliable iohexol plasma clearance method in routine monitoring of the renal function (gfr) in children. different parameters of renal function will be compared to the gold standard multiple sample points procedure of iohexol clearance.


Eligibility criteria:
inclusion criteria: * age \< 18 years * clinical indication for measurement of glomerular filtration rate exclusion criteria: * previous serious reaction on iohexol

Keywords: glomerular filtration rate kidney disease child iohexol cystatin c measurement of kidney function in children